🇺🇸 ZD1839 (Gefitinib) in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Abdominal Rigidity — 1 report (10%)
  2. Arthralgia — 1 report (10%)
  3. Colon Cancer — 1 report (10%)
  4. Diarrhoea — 1 report (10%)
  5. Fatigue — 1 report (10%)
  6. General Physical Health Deterioration — 1 report (10%)
  7. Malignant Neoplasm Progression — 1 report (10%)
  8. Metastases To Lung — 1 report (10%)
  9. Metastases To Thorax — 1 report (10%)
  10. Nausea — 1 report (10%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is ZD1839 (Gefitinib) approved in United States?

ZD1839 (Gefitinib) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ZD1839 (Gefitinib) in United States?

AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.